Attovia Therapeutics, Inc.

What they do

Attovia develops next-generation biotherapeutics for immune-mediated diseases with high unmet need. Its lead candidate, ATTO-1310, is a half-life extended ATTOBODY-based Fc-fusion protein targeting the itch cytokine IL-31. The pipeline also includes ATTO-2306, a bispecific targeting IL-31 and IL-13, and ATTO-1091, a trispecific targeting TL1A, IL-23p19, and integrin alpha4beta7. The company is based in San Carlos, California.

Revenue drivers

• ATTO-1310 — Lead clinical program for pruritic diseases; no product revenue yet, company reported $450,000 revenue in Q2 2026 versus $0 in Q2 2025.
• ATTO-2306 — Preclinical bispecific for atopic dermatitis and other immune-mediated skin diseases; IND-enabling activities ongoing, Phase 1 planned for 1H 2027.
• ATTO-1091 — Preclinical trispecific for inflammatory bowel disease; IND-enabling activities ongoing, Phase 1 planned for 1H 2027.

Recent performance

For the quarter ended June 30, 2026, Attovia reported revenue of $450,000 compared to $0 for the same period in 2025. The company had total assets of $128.3 million, total liabilities of $15.6 million, and cash and equivalents of $32.8 million as of June 30, 2026. Shareholder equity was negative $145.5 million. The company completed an upsized IPO with gross proceeds of approximately $332.4 million, which is not reflected in the June 30 balance sheet.

Strategy

Attovia is advancing ATTO-1310 toward two Phase 2 studies in chronic pruritus of unknown origin and high-itch atopic dermatitis, both planned for the first half of 2027. Complete Phase 1b data for ATTO-1310 are expected in the fourth quarter of 2026. The company is progressing ATTO-2306 and ATTO-1091 toward the clinic in the first half of 2027. It is also advancing ATTO-006, a conditional bispecific, toward development candidate nomination by year-end 2026. Management states the IPO proceeds extend cash runway into 2030.

Risks

• Early-stage clinical risk — ATTO-1310 has only preliminary Phase 1b proof-of-concept data; complete data are not yet available and future trials may not replicate early results.
• No product revenue — The company reported only $450,000 in revenue for Q2 2026 and has no approved products, so it depends on financing to fund operations.
• Negative shareholder equity — As of June 30, 2026, shareholder equity was negative $145.5 million, reflecting accumulated deficits and redeemable convertible preferred stock.
• Regulatory and development delays — Phase 2 studies and Phase 1 initiations are planned but not yet started; timelines could slip due to regulatory feedback or enrollment challenges.

Outlook

Management expects complete Phase 1b data for ATTO-1310 in the fourth quarter of 2026 and plans to initiate two Phase 2 studies in the first half of 2027. Phase 1 initiation for ATTO-2306 and ATTO-1091 is also expected in the first half of 2027. The company states its upsized IPO proceeds of $332.4 million extend cash runway into 2030.